Navigation Links
Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
Date:11/17/2010

Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany

 

QUÉBEC CITY, Nov. 17 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS, TSX: AEZ), ("the Company") today presented posters on encouraging preclinical results for AEZS-129 and AEZS-132, two novel orally active compounds with anti-tumor effects. Data shows that AEZS-129 and AEZS-132 block important signalling pathways (PI3K/Akt and Ras/Raf/Mek/Erk) which contribute to the proliferation and survival of cancer cells. Targeting these multiple signalling pathways could result in improved treatment efficacy for such cancers as lung, colon, prostate, breast, endometrial cancer and melanoma. Both posters were presented by Irene Seipelt, Associate Director, Discovery and Preclinical Development at Aeterna Zentaris, during the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics currently held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "Data from the studies on AEZS-129 and AEZS-132 presented today, demonstrate that these two novel orally active anti-cancer compounds can inhibit the growth of tumor cells without critical safety issues. They are also prime examples of our innovative drug development programs in oncology, using molecules that work by using a targeted approach in order to tailor the treatment to a patient's specific condition and tumor characteristics. Although still in preclinical development, we believe AEZS-129 and especially the first-in-class dual PI3K/Erk inhibitor, AEZS-132, could be part of the next generation of cancer treatments." AEZS-129Abstract #98:  
"AEZS-129, an orally active PI3K inhibitor in preclinical development," I. Seipelt, E. Guenther, S. Baasner, L. Blumenstein, G. Mueller, J. Fensterle, J. Engel, M. Teifel, M. Gerlach Summary:  AEZS-129 has been identified as a highly potent and selective inhibitor of PI3K. The compound inhibits the PI3K/Akt signalling pathway both in-vitro and in-vivo and leads to growth inhibition of tumor cells. The compound was well tolerated during the 4 week treatment period and showed substantial tumor growth inhibition in different mouse xenograft tumor models. 

This abstract is available at: http://poster-submission.com/search/sresult AEZS-132 Abstract #197:   "AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects," I. Seipelt, M. Gerlach, S. Baasner, L. Blumenstein, G. Mueller, B. Aicher, J. Engel, E. Guenther, M. Teifel Summary:  AEZS-132 is the first-in-class dual PI3K/Erk inhibitor being selected as the optimized lead compound for further development. The compound is a unique orally active low molecular weight dual PI3K/Erk inhibitor derived from Aeterna Zentaris' medicinal chemistry program. Due to its dual PI3K and Erk inhibition, a broad anti-tumor activity is expected in tumors with over-activation of both pathways. AEZS-132 demonstrated prolonged plasma exposure when given orally in mice. Significant tumor inhibition resulted from mouse xenograft models with human colon, endometrium and lung tumors.

This abstract is available at: http://poster-submission.com/search/sresult/140 About Aeterna Zentaris Inc. Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, and endometrial cancer as well as multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Philadelphia, PA (PRWEB) , ... January 20, 2017 , ... ... are transforming healthcare treatment options for patients. Vironika, a spin out from The Wistar ... are both taking lab space at 3624 Market Street. , Vironika is developing ...
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... India , Jan. 19, 2017  Market Research Future has ... Global Market for Liquid Biopsy is growing rapidly and expected to ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a ... growth figures and boom in the coming future. There has been ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the ... 2025" report to their offering. Report ... provides a detailed analysis on current and future market trends to identify ... market values as the base numbers Key market trends ...
Breaking Biology Technology:
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/16/2016)... The global wearable medical device market, in terms of ... USD 5.31 billion in 2016, at a CAGR of 18.0% during ... ... in medical devices, launch of a growing number of smartphone-based healthcare ... healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... , Dec. 15, 2016 ... driving experience, health wellness and wellbeing (HWW), ... one in three new passenger vehicles begin ... recognition, gesture recognition, heart beat monitoring, brain ... monitoring, facial monitoring, and pulse detection. These ...
Breaking Biology News(10 mins):